American Vanguard Corporation (AVD) reported a constructive start to 2024 with solid top-line growth, earnings leverage from cost controls, and a clear strategic focus on transformation despite near-term cash-flow headwinds and regulatory headwinds around the Dacthal herbicide. For the quarter ended March 31, 2024, revenue rose 8% year-over-year to $135.1 million, gross margin expanded modestly to 31.4% from 30.8% a year earlier, and EBITDA (adjusted) surged 35% as operating leverage improved. Management underscored ongoing transformation initiatives intended to lift EBITDA by at least $15 million on an annualized basis by 2026, albeit with near-term spend that temporarily presses 2024 profitability. The firm also noted favorable demand in U.S. Crop and Non-crop segments and modest international strength, while Dacthal-related sales were suspended pending EPA review, a development that will affect full-year guidance and revenue composition in 2024 and beyond. Management framed 2024 as a transition year where early reinvestment supports longer-term margin expansion and capital-light growth, with more meaningful EBITDA acceleration anticipated in 2025 and 2026 as transformation benefits materialize.